Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1419 | Olaparib | PARP | Misc | Inf | 0.6322 | 0.0273 | -0.0012 | 2.1535 | 5.2752 | 0.95353 |
HCC1395 | Vorinostat | HDAC | Misc | 3.2812 | -0.0589 | 0.1137 | 0.0365 | 2.1496 | 3.8175 | 0.99171 |
HCC1428 | Volasertib | PLK | Cell cycle | 0.018634 | -0.0388 | 0.4063 | 0.0917 | 2.1456 | 0.018507 | 0.99276 |
MCF 10A | Cisplatin | Chemo | Chemotherapy | 4.2937 | 0.3794 | 0.0952 | 0.0149 | 2.1287 | 2.4561 | 0.99519 |
MDA-MB-468 | Buparlisib | pan PI3K | PI3K/mTOR | 0.83168 | -0.5157 | 0.3573 | 0.2010 | 2.1267 | 1.1738 | 0.99824 |
HCC1937 | Tivantinib | MET | RTK | 0.64919 | -0.0621 | 0.2925 | 0.0799 | 2.1267 | 0.69626 | 0.99463 |
CAL-85-1 | Abemaciclib | CDK4/6 | Cell cycle | 1.3003 | -0.2236 | 0.2357 | 0.0485 | 2.1239 | 1.5776 | 0.99317 |
CAL-85-1 | Dinaciclib | pan CDK | Cell cycle | 0.0046904 | -0.2406 | 0.6880 | 0.1122 | 2.1120 | 0.005589 | 0.99744 |
HCC1419 | Vorinostat | HDAC | Misc | 1.735 | -0.2557 | 0.1917 | 0.0407 | 2.1116 | 2.1704 | 0.99173 |
MDA-MB-468 | Topotecan | Topo I | Chemotherapy | 0.015779 | -0.6577 | 1.0692 | 0.4464 | 2.1036 | 0.023029 | 0.99528 |
HCC70 | Etoposide | Topo II | Chemotherapy | 0.36498 | -0.1518 | 0.4535 | 0.0513 | 2.1004 | 0.41879 | 0.96872 |
SUM1315MO2 | Doxorubicin | Chemo | Chemotherapy | 0.018222 | -0.0635 | 0.5132 | 0.1324 | 2.0980 | 0.016338 | 0.96491 |
SUM159PT | Tivantinib | MET | RTK | 0.37997 | -0.1921 | 0.3954 | 0.1806 | 2.0717 | 0.4458 | 0.9982 |
BT-20 | Taxol | Chemo | Chemotherapy | 0.0020158 | -0.5760 | 0.9854 | 0.4456 | 2.0677 | 0.0028795 | 0.99355 |
Hs 578T | Tivantinib | MET | RTK | 0.33668 | -0.3204 | 0.4411 | 0.2071 | 2.0560 | 0.42597 | 0.99878 |
HCC1419 | AZD7762 | CHK1/2 | Cell cycle | 0.068618 | -0.0826 | 0.5614 | 0.1156 | 2.0553 | 0.072481 | 0.98917 |
MDA-MB-361 | AZD7762 | CHK1/2 | Cell cycle | 0.0076402 | -0.6753 | 1.0533 | 0.2116 | 2.0458 | 0.010426 | 0.97675 |
CAL-85-1 | Volasertib | PLK | Cell cycle | 0.0032652 | -0.2891 | 0.7316 | 0.1652 | 2.0442 | 0.0039314 | 0.99429 |
HCC1419 | Luminespib | HSP90 | Misc | 0.0069643 | -0.2968 | 0.6506 | 0.1579 | 2.0439 | 0.0087353 | 0.99699 |
HCC38 | AZD7762 | CHK1/2 | Cell cycle | 0.0094764 | -0.3341 | 0.9185 | 0.2951 | 2.0434 | 0.01177 | 0.98869 |
HCC70 | Doxorubicin | Chemo | Chemotherapy | 0.010621 | -0.7794 | 0.7867 | 0.1459 | 2.0410 | 0.014138 | 0.93856 |
Hs 578T | Etoposide | Topo II | Chemotherapy | 0.41322 | -0.1361 | 0.3770 | 0.1666 | 2.0332 | 0.46109 | 0.99901 |
CAMA-1 | Dinaciclib | pan CDK | Cell cycle | 0.014558 | -0.4849 | 0.6062 | 0.1927 | 2.0283 | 0.019954 | 0.99839 |
CAL-85-1 | Taxol | Chemo | Chemotherapy | 0.0027273 | -0.3464 | 0.7931 | 0.3351 | 2.0210 | 0.0033785 | 0.95638 |
BT-549 | Buparlisib | pan PI3K | PI3K/mTOR | 1.419 | -0.2716 | 0.2487 | 0.0802 | 2.0178 | 1.8107 | 0.99484 |